

Supplementary Table 1: Proportion of patients with therapeutic success at visit 2, stratified by exacerbations in the last 12 months

Exacerbations in the last 12 months	Proportion of patients with therapeutic success	N	%	95% CI
0	Therapy successful	250	56.82	52.04–61.5
	Therapy not successful	190	43.18	
	Total	440	100.00	
1	Therapy successful	236	67.43	62.24–72.32
	Therapy not successful	114	32.57	
	Total	350	100.00	
≥2	Therapy successful	270	77.14	72.38–81.44
	Therapy not successful	80	22.86	
	Total	350	100.00	
Total	Therapy successful	756	66.32	63.49–69.06
	Therapy not successful	384	33.68	
	Total	1140	100.00	

CI, confidence interval.

Supplementary Table 2: Proportion of patients with therapeutic success at visit 2, stratified by GOLD spirometric classification

GOLD spirometric classification	Proportion of patients with therapeutic success	N	%	95% CI
1	Therapy successful	12	54.55	32.21–75.61
	Therapy not successful	10	45.45	
	Total	22	100.00	
2	Therapy successful	338	67.20	62.90–71.29
	Therapy not successful	165	32.80	
	Total	503	100.00	
3	Therapy successful	278	65.26	60.53–69.78
	Therapy not successful	148	34.74	
	Total	426	100.00	
4	Therapy successful	69	60.00	50.45–69.02
	Therapy not successful	46	40.00	
	Total	115	100.00	
Missing	Therapy successful	59	79.73	68.78–88.19
	Therapy not successful	15	20.27	
	Total	74	100.00	
Total	Therapy successful	756	66.32	63.49–69.06
	Therapy not successful	384	33.68	
	Total	1140	100.00	

CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

Supplementary Table 3: Proportion of patients with therapeutic success at visit 2, stratified by ICS treatment at baseline

Treatment with ICS	Proportion of patients with therapeutic success	N	%	95% CI
Baseline ICS	Therapy successful	58	69.05	58.02–78.69
	Therapy not successful	26	30.95	
	Total	84	100.00	
No baseline ICS	Therapy successful	698	66.10	63.15–68.95
	Therapy not successful	358	33.90	
	Total	1056	100.00	
Total	Therapy successful	756	66.32	63.49–69.06
	Therapy not successful	384	33.68	
	Total	1140	100.00	

CI, confidence interval; ICS, inhaled corticosteroids.

Supplementary Table 4: Mean absolute change in CCQ score from visit 1 to visit 2, stratified by prior COPD maintenance treatment and GOLD groups

CCQ domain	Maintenance-naïve (n=959)	Pretreated – LABA only or LAMA only or LABA+ICS (n=181)	GOLD group		
			B (n=735)	C (n=128)	D (n=277)
Symptom	0.88±1.08 (0.81–0.95)	0.60±0.94 (0.47–0.74)	0.72±0.99 (0.65–0.80)	1.06±1.23 (0.85–1.28)	1.03±1.13 (0.90–1.16)
Functional state	0.79±1.04 (0.73–0.86)	0.51±1.11 (0.35–0.67)	0.62±1.00 (0.55–0.69)	0.91±1.24 (0.70–1.13)	1.01±1.05 (0.89–1.14)
Mental state	0.79±1.33 (0.71–0.87)	0.43±1.34 (0.23–0.62)	0.64±1.27 (0.54–0.73)	0.90±1.37 (0.66–1.14)	0.91±1.49 (0.73–1.09)
Total CCQ score	0.83±0.95 (0.77–0.89)	0.53±0.89 (0.40–0.66)	0.66±0.86 (0.60–0.73)	0.97±1.14 (0.77–1.17)	1.00±1.03 (0.88–1.12)

Data are presented as mean±SD (95% CI).

CCQ, Clinical COPD Questionnaire; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β_2 -agonist; LAMA, long-acting muscarinic antagonist; SD, standard deviation.